Patent US4751078A successfully refreshed from Google Patents.
US4751078A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for the purification of gamma interferon
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1985-07-03
•
Granted: 1988-06-14
•
Expires: 2005-07-03
Abstract
Abstract A process is disclosed for purifying gamma interferon from various contaminants resulting from disruption of the cell in which the interferon was produced. The process provides for sequential removal of (a) nucleic acids, (b) negatively charged contaminating proteins, (c) positively charged contaminating proteins and (d) low and high molecular weight impurities.
Inventors
- 👤 Tattanahalli L. Nagabhushan
- 👤 Paul P. Trotta
- 👤 Hung V. Le
- 👤 Gail F. Seelig
- 👤 Robert A. Kosecki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 17:09
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; Y; Y10; Y10S; Y10S435/00; Y10S435/811
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
64 words
A process of increasing the purity of gamma interferon comprising sequentially removing (1) nucleic acids by precipitation with polyethyleneimine; (2) negatively charged contaminating proteins by column chromatography with a weak base anion exchange resin; (3) positively charged contaminating proteins by column chromatography with a weak acid cation exchange resin; (4) low and high molecular weight materials by permeation chromatography with a gel filtration resin.
Claim 2
Dependent Claim
64 words
A process of increasing the purity of gamma interferon comprising sequentially removing (1) nucleic acids by precipitation with polyethyleneimine; (2) negatively charged contaminating proteins by column chromatography with a weak base anion exchange resin; (3) positively charged contaminating proteins by column chromatography with a weak acid cation exchange resin; (4) low and high molecular weight materials by permeation chromatography with a gel filtration resin.
Claim 3
Dependent Claim
15 words
The process of claim 1 where the anion exchange resin is a quartenary aminoethyl resin.
Claim 4
Dependent Claim
16 words
The process of claim 1 where the weak acid cation exchange resin is a carboxymethyl resin.
Claim 5
Dependent Claim
18 words
The process of claim 1 where the gel filtration resin is selected from Sephadex G-100 and Sephacryl S-200.
Claim 6
Dependent Claim
15 words
The process of claim 1 where the gamma interferon-containing solution is concentrated after step 2.
Claim 7
Dependent Claim
15 words
The process of claim 5 where the solution is concentrated by precipitation with ammonium sulfate.
Claim 8
Dependent Claim
26 words
The process of claim 1 where the gamma interferon-containing solution is concentrated by ultrafiltration, precipitation with ammonium sulfate or ultrafiltration followed by precipitation with ammonium sulfate.
Claim 9
Dependent Claim
39 words
The process of claim 1 where high molecular weight hydrophobic materials are removed from the gamma interferon-containinq solution either immediately after removal of the positively charged proteins or immediately after removal of the high and low molecular weight materials.
Claim 10
Dependent Claim
27 words
The process of claim 1 where the process includes a final step of dialysis against cysteine containing buffer in an oxygen-free environment of the gamma interferon-containing solution.
Claim 11
Dependent Claim
23 words
The process of claim 1 where the gamma interferon in the impure gamma interferon-containing solution is recombinant gamma interferon recovered from E. Coli.
Claim 12
Independent Claim
116 words
A method of purifying solutions containing recombinant gamma interferon recovered from E. Coli cells by disrupting the gamma interferon containing cells, separating the components of the cells by centrifugation and collecting the supernatant solution comprising (1) adding polyethyleneimine to the supernatant solution; (2) centrifuging the mixture to separate the resulting precipitate from the supernatant solution; (3) adsorbing the solution from step 2 on a column containing an anion exchange resin; (4) eluting the adsorbed material; (5) adsorbing the eluate from step 4 onto a column containing a cation exchange resin; (6) eluting the adsorbed material; (7) adsorbing the eluate from step 6 onto a column containing a gel filtration resin; and (8) eluting the adsorbed material.
Claim 13
Independent Claim
116 words
A method of purifying solutions containing recombinant gamma interferon recovered from E. Coli cells by disrupting the gamma interferon containing cells, separating the components of the cells by centrifugation and collecting the supernatant solution comprising (1) adding polyethyleneimine to the supernatant solution; (2) centrifuging the mixture to separate the resulting precipitate from the supernatant solution; (3) adsorbing the solution from step 2 on a column containing an anion exchange resin; (4) eluting the adsorbed material; (5) adsorbing the eluate from step 4 onto a column containing a cation exchange resin; (6) eluting the adsorbed material; (7) adsorbing the eluate from step 6 onto a column containing a gel filtration resin; and (8) eluting the adsorbed material.
Claim 14
Dependent Claim
24 words
The process of claim 11 where the adsorbed material from step 3 is eluted with a buffer comprising sodium 4-(2-hydroxyethyl)-1-piperazine-propane sulfonate and an antioxidant.
Claim 15
Dependent Claim
10 words
The process of claim 12 where the antioxidant is 2-mercaptoethanol.
Claim 16
Dependent Claim
22 words
The process of claim 12 where the adsorbed material from step 5 is eluted with a buffer comprising Tris-HCl and an antioxidant.
Claim 17
Dependent Claim
19 words
The process of claim 12 where the adsorbed material from step 7 is eluted with a buffer comprising Tris-HCl.
Claim 18
Dependent Claim
35 words
The process of claim 15 where the weak base anion exchahge resin is a quartenary aminoethyl resin; the weak acid cation exchange resin is a carboxymethyl resin; and the gel filtration resin is Sephadex G-100.
References Cited (Backward Citations)
US4440675A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-06-14 | 1991-12-14 | 1992-06-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-06-14 | 1995-12-14 | 1996-06-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-06-14 | 1999-12-14 | 2000-06-14 | $7700.00 | Window Closed / Lapsed |